脓毒性休克早期多模式血管加压药策略:TRICYCLE随机对照试验结果
TRICYCLE为II期RCT,纳入79例接受≥0.15 µg/kg/min去甲肾上腺素碱基的脓毒性休克患者,随机分为早期多模式血管加压药组(血管紧张素II+血管加压素+去甲肾上腺素)或经典阶梯组(先去甲肾上腺素加量,再加血管加压素,最后血管紧张素II或其他)。主要终点血浆肾素浓度下降速度更快(2.61%/h vs 1.67%/h,p=0.015),乳酸下降亦更快,72h SOFA降低3分 vs 0分(p=0.018),快速性心律失常更少(15.6% vs 68.6%),但ICU及28天死亡率无差异。
要点
- 纳入标准:脓毒性休克且去甲肾上腺素碱基剂量≥0.15 µg/kg/min;排除标准原文未提及。
- 干预组早期同时给予血管紧张素II、血管加压素和去甲肾上腺素;对照组按去甲肾上腺素加量→血管加压素→血管紧张素II或其他血管加压药阶梯升级。
- 主要终点血浆肾素浓度下降更快(2.61%/h vs 1.67%/h,p=0.015),乳酸下降亦更快(1.53%/h vs 1.01%/h,p=0.006)。
- 72h SOFA评分干预组降低3分 vs 对照组0分(p=0.018);快速性心律失常发生率15.6% vs 68.6%(p<0.01)。
- ICU死亡率(26.3% vs 41.5%,RR 0.635,95%CI 0.33–1.21)及28天死亡率(36.8% vs 46.3%,RR 0.795,95%CI 0.47–1.35)无显著差异;本II期试验未以死亡率差异为效能目标。
适用人群与场景
- 脓毒性休克患者,且正在接受去甲肾上腺素碱基剂量≥0.15 µg/kg/min。
- 排除标准原文未提及。
- 研究场景为ICU(原文未明确院前或急诊场景)。
诊断标准与关键阈值
- 脓毒性休克诊断标准原文未提及具体标准名称或界值。
- 启动多模式血管加压药策略的触发条件:去甲肾上腺素碱基剂量≥0.15 µg/kg/min。
- 主要终点为血浆肾素浓度变化,原文未给出肾素浓度的绝对阈值或目标值。
处置流程与药物剂量
- 干预组:早期同时给予血管紧张素II、血管加压素和去甲肾上腺素(原文未给出各药具体剂量、给药途径、频次或疗程)。
- 对照组:经典阶梯策略,先去甲肾上腺素剂量增加,随后加用血管加压素,之后加用血管紧张素II或其他血管加压药(原文未给出各步骤具体剂量或升级阈值)。
- 原文未提及液体复苏、激素或其他辅助治疗的具体方案。
红旗征与不能漏的情况
- 快速性心律失常:干预组发生率15.6% vs 对照组68.6%(p<0.01),对照组中需警惕。
- 原文未提及其他需立刻处理或不能漏诊的具体情况。
研究设计与关键结果
- 研究类型:II期随机对照试验(RCT),样本量79例(干预组38例,对照组41例),中心数原文未提及。
- 人群:脓毒性休克且去甲肾上腺素碱基剂量≥0.15 µg/kg/min的患者。
- 干预 vs 对照:早期多模式血管加压药(血管紧张素II+血管加压素+去甲肾上腺素)vs 经典阶梯血管加压药策略。
- 主要终点:血浆肾素浓度下降速度干预组2.61%/h vs 对照组1.67%/h(p=0.015)。
- 关键次要终点:乳酸下降速度1.53%/h vs 1.01%/h(p=0.006);72h SOFA评分降低3分 vs 0分(p=0.018);快速性心律失常15.6% vs 68.6%(p<0.01)。
- 非预设分析:72h内去甲肾上腺素等效剂量下降速度无差异(-5.41%/h vs -5.19%/h,p=0.47);前24h干预组下降更快(-6.87%/h vs -3.03%/h,p<0.0004)。
- 死亡率:ICU死亡率26.3% vs 41.5%(RR 0.635,95%CI 0.33–1.21,p=0.235);28天死亡率36.8% vs 46.3%(RR 0.795,95%CI 0.47–1.35,p=0.494)。
- 本试验未以死亡率差异为效能目标。
证据类型、等级与局限
- 证据类型:II期随机对照试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:样本量小(79例),II期试验未以死亡率差异为效能目标,部分分析为非预设分析,中心数及盲法设计原文未提及。
对床旁实践的改变
- 对于脓毒性休克且去甲肾上腺素碱基剂量≥0.15 µg/kg/min的患者,早期多模式血管加压药策略可更快降低血浆肾素和乳酸水平,并改善72h SOFA评分。
- 该策略可能减少快速性心律失常的发生,但原文未给出具体用药剂量和方案细节,不能直接推广为标准化治疗。
- 该策略未显示死亡率获益,原文结论为提供依据开展更大规模试验以评估患者中心结局。
- 适用人群:脓毒性休克且去甲肾上腺素碱基剂量≥0.15 µg/kg/min者;不适用人群及排除标准原文未提及。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT06155812。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Given multifactorial mechanisms driving vasodilation in septic shock, there is a strong physiological rationale for early initiation of multiple vasopressors (angiotensin II, vasopressin and norepinephrine) with complementary mechanisms of action. Such an approach could more effectively counteract the complex pathophysiological processes characteristic of septic shock. Here we tested the physiological and clinical effects of an early multimodal vasopressor strategy in patients with septic shock.
METHODS: We randomly assigned patients with septic shock receiving ≥ 0.15 µg/kg/min of norepinephrine base to either intervention (early multimodal vasopressor administration: angiotensin II, vasopressin, and norepinephrine) group or control (classic stepwise vasopressor administration: norepinephrine dose increase followed by vasopressin and then by angiotensin II or other vasopressors) group. The primary outcome was change in plasma renin concentrations. This phase II trial was not powered to detect differences in mortality.
RESULTS: A total of 79 patients were included (intervention group: n = 38, control group: n = 41). We observed a faster decline in plasma renin concentrations (2.61% per hour vs. 1.67% per hour; p = 0.015) and lactate concentrations (1.53% per hour vs. 1.01% per hour; p = 0.006) during the first 72 h in the intervention group compared to the control group. At 72 h, Sequential Organ Failure Assessment (SOFA) score was reduced by 3 points in the intervention group vs. 0 in the control group (p = 0.018). In the additional non-prespecified analyses, norepinephrine equivalent (NEE) dose decreased at a similar rate in the intervention and control groups over 72 h (- 5.41% per hour vs. -5.19% per hour; p = 0.47), whereas over the first 24 h, NEE dose decreased significantly faster in the intervention group (- 6.87% per hour vs. -3.03% per hour; p < 0.0004). The incidence of tachyarrhythmias was significantly lower in the intervention group (15.6% vs. 68.6%; p < 0.01). Intensive care unit mortality (26.3% vs. 41.5%; RR 0.635; 95% CI 0.33 to 1.21; p = 0.235) and 28-day mortality (36.8% vs. 46.3%; RR 0.795; 95% CI 0.47 to 1.35; p = 0.494) were similar.
CONCLUSION: Early multimodal vasopressor therapy with Ang II, vasopressin and norepinephrine in patients with septic shock demonstrated promising physiological effects. These findings provide a rationale for a larger trial to assess whether early multimodal vasopressor therapy improves patient-centered outcomes.
TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT06155812. URL: https://clinicaltrials.gov/study/NCT06155812?term=NCT06155812&rank=1 . Trial registration date: 4 December 2023.
参考来源
- Kalamar Ž, Landoni G, Gorenjak M, et al. Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial. Crit Care. 2026. PMID: 42827265. doi:10.1186/s13054-026-06323-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。